Serial No.: 10/501,841 Group Art Unit No.: 1643

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-16. (Canceled)

17. (Currently Amended) A method for treating chronic lymphocytic leukemia (CLL) in a mammalian subject comprising administering to said subject an effective amount of an isolated monoclonal antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4 wherein said monoclonal antibody has a binding constant for SEQ ID NO:4 that exceeds 10³L/mol., and does not react detectably with polypeptides unrelated to SEQ ID NO: 4.

18-20. (Canceled)

- 21. (Previously Presented) The method of claim 17, wherein said antibody is a humanized antibody.
- 22. (Previously Presented) The method of claim 17, wherein said antibody is a chimeric antibody.
- 23. (Previously Presented) The method of claim 17, wherein said antibody is a Fab fragment.
- 24. (Currently Amended) The method of claim 17, wherein said antibody is a Fv fragment fragment.
- 25. (Previously Presented) The method of claim 17, wherein said antibody is a scFv.
- 26. (Previously Presented) The method of claim 17, wherein said antibody further comprises a therapeutic moiety.

Serial No.: 10/501,841 Group Art Unit No.: 1643

- 27. (Previously Presented) The method of claim 26, wherein the therapeutic moiety is a radionuclide.
- 28. (Previously Presented) The method of claim 27, wherein the radionuclide is a member selected from the group consisting of: ⁹⁰Y, ¹²³I, ¹²⁵I, ¹³¹I, ¹⁸⁶Re, ²¹¹At, and ²¹²Bi.

29-31. (Canceled)

- 32. (Previously Presented) The method of claim 27, wherein the mammalian subject is a human.
- 33. (Previously Presented) The method of claim 17, wherein administration is intravenous.

34-53. (Canceled)

54. (Previously Presented) The method of claim 17, wherein the monoclonal antibody is not a bi-specific antibody.